Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
Vascular Medicine
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Bounameaux, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bounameaux, H.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Unfractionated versus low-molecular-weight heparin in the treatment of venous thromboembolism

Henri Bounameaux

Division of Angiology and Hemostasis, Department of Internal Medicine, University of Geneva School of Medicine, Geneva, Switzerland

Low-molecular-weight heparin (LMWH) fractions are prepared from standard unfractionated heparin (UFH) and are thus similar to UFH in many aspects. The main advantages of this new class of antithrombotic agents as compared with UFH are: (1) an improved bioavail-ability and a prolonged half-life, which alleviate cumbersome laboratory monitoring and may permit one single daily subcutaneous injection; and (2) an improved efficacy-to-safety ratio, with less bleeding despite similar or improved efficacy. For these reasons, LMWH is progressively replacing UFH for preventing postoperative thromboembolism and for treating established deep vein thrombosis and pulmonary embolism. However, the effects of the new compounds need to be evaluated carefully in some other indications (arterial thrombosis, unstable angina, or myocardial infarction - the latter also in conjunction with thrombolytic treatment) before they can generally replace UFH in pharmacotherapy.

Key Words: anticoagulation • low-molecular-weight heparin • unfractionated heparin

Vascular Medicine, Vol. 3, No. 1, 41-46 (1998)
DOI: 10.1177/1358836X9800300109
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 pdiHome page
M. N. Schilte, J. Loureiro, E. D. Keuning, P. M. t. Wee, J. W.A.M. Celie, R. H.J. Beelen, and J. van den Born
LONG-TERM INTERVENTION WITH HEPARINS IN A RAT MODEL OF PERITONEAL DIALYSIS
Perit. Dial. Int., January 1, 2009; 29(1): 26 - 35.
[Abstract] [Full Text] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
H. Van Aken, C. Bode, H. Darius, C. Diehm, A. Encke, D. C. Gulba, S. Haas, W. Hacke, W. Puhl, M. Quante, et al.
State-of-the-Art Review: Anticoagulation: The Present and Future
Clinical and Applied Thrombosis/Hemostasis, July 1, 2001; 7(3): 195 - 204.
[Abstract] [PDF]